<DOC>
	<DOC>NCT01946971</DOC>
	<brief_summary>This study is crossover study to evaluate safety and efficacy of lansoprazole in preterm infants with gastroesophageal reflux.</brief_summary>
	<brief_title>Lansoprazole in Preterm Infants With Gastroesophageal Reflux (GER)</brief_title>
	<detailed_description />
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Lansoprazole</mesh_term>
	<mesh_term>Dexlansoprazole</mesh_term>
	<criteria>preterm infant symptoms suspecting gastroesophageal reflux unstable general conditions due infection or acute illness congenital anomaly in upper gastrointestinal tract including esophagus drug history of H2, proton pump inhibitor, blocker during last 1 week medication of warfarin, carbamazepine, phenytoin, rifampin inappropriate clinical conditions judged by researchers</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>6 Months</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>